Eli Lilly’s Psoriasis-Obesity Combo Therapy Shows Promise Amid Stock Dip

Eli Lilly and Company shares fell 1.65% to $1,018.92 following Phase 3b trial results for its Taltz-Zepbound combination therapy. The treatment demonstrated significant efficacy in patients with both psoriasis and obesity, yet the market reaction was unexpectedly negative.

The TOGETHER-PsO trial enrolled 274 adults with moderate-to-severe plaque psoriasis and comorbid obesity. After 36 weeks, the combination therapy showed 27.1% of participants achieved complete skin clearance with ≥10% weight loss—a 4.6x improvement over Taltz monotherapy. Secondary endpoints revealed a 40% higher PASI 100 response rate versus standalone treatment.

Market analysts suggest the decline reflects profit-taking after Eli Lilly's 68% YTD rally rather than therapeutic shortcomings. The dual-mechanism approach positions Lilly favorably in the competitive metabolic disease space, though cryptocurrency investors should note this as a traditional biotech play with no direct digital asset implications.